Latest Licensing Agreements News

Activeport Group Ltd reported steady revenue of $2.5 million in Q2 FY25, maintaining a stable cost structure post-restructure and positioning itself for growth through new projects and a significant GPU orchestration licensing deal.

Equity Story Group Ltd (ASX:EQS) reports a robust December quarter marked by significant growth in funds under management, membership fees, and capital markets revenue, alongside strategic cost reductions positioning the company for sustained 2025 growth.

Bluechiip Limited advances its strategic repositioning with a new licensing agreement valued up to USD 750,000 alongside ongoing efforts to lift its trading suspension and grow sales.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

PARKD Ltd reports substantial structural completions on flagship projects and positive operating cash flow in Q2 FY25, setting the stage for licensing negotiations with Fielders.

BrainChip Holdings reports a US$20 million cash balance and key defense contracts in its December 2024 quarterly update, underscoring its growing foothold in neuromorphic AI commercialization.

Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.

Vection Technologies has reported a milestone positive net cash flow in its traditionally weak quarter, driven by a 60% half-on-half revenue surge and strategic acquisition integration.

Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.